Health-state utility of patients with HER2-positive breast cancer in Vietnam: A multicenter cross-sectional study
PLOS ONE · 2024
DOI: 10.1371/journal.pone.0303011 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift PLOS ONE, 2024. Verfasst von Tram Nguyen Nguyet Luu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Pharmacy, Hue University of Medicine and Pharmacy, Hue University, Hue, Vietnam. Hauptthemen laut MEDLINE: Breast Neoplasms, Erb-b2 Receptor Tyrosine Kinases, Quality of Life. Die Arbeit nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer may have poor prognoses and short overall and disease-free survival. Most previous studies focused on assessing the quality of life and health-state utility of the general population of breast cancer patients. The number of studies for HER2-positive breast cancer patients is negligible. This study investigated the health-state utility and its associated factors among Vietnamese patients with HER2-positive breast cancer.
Methods
We conducted face-to-face interviews with 301 HER2-positive breast cancer patients to collect data. Their health-state utility was measured via the EQ-5D-5L instrument. The Mann-Whitney U and Kruskal-Wallis tests were employed to compare the differences in utility scores between two groups and among three groups or more, respectively. Factors associated with patients’ heath-state utility were identified via Tobit regression models.
Results
Pain/discomfort (56.1%) and anxiety/depression (39.5%) were the two issues that patients suffered from the most, especially among metastatic breast cancer patients. The severity of distress (depression, anxiety, and stress) in patients was relatively mild. Of 301 patients, their average utility score was 0.86±0.17 (range: 0.03–1.00), and the average EQ-visual analogue scale (VAS) score was 69.12±12.60 (range: 30–100). These figures were 0.79±0.21 and 65.20±13.20 for 102 metastatic breast cancer patients, significantly lower than those of 199 non-metastatic cancer patients (0.89±0.13 and 71.13±11.78) ( p
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Faculty of Pharmacy, Hue University of Medicine and Pharmacy, Hue University, Hue, Vietnam.
- Faculty of Pharmaceutical Management and Economics, Hanoi University of Pharmacy, Hanoi, Vietnam.
- Department of Anesthesiology and Intensive Care, Hue University of Medicine and Pharmacy, Hue University, Hue, Vietnam.
- Faculty of Public Health, Hue University of Medicine and Pharmacy, Hue University, Hue, Vietnam.
- Vietnam National Cancer Institute, Vietnam National Cancer Hospital, Hanoi, Vietnam.
- Department of Medical Ethics and Medical Sociology, Hanoi Medical University, Hanoi, Vietnam.
ORCID-Profile: Dai Xuan Dinh, Thang Binh Tran
Zitieren
APA
Luu, T. N. N., Dinh, D. X., Tran, T. X., Tran, T. B., Tran, H. T., Pham, K. H. T., & Nguyen, H. T. T. (2024). Health-state utility of patients with HER2-positive breast cancer in Vietnam: A multicenter cross-sectional study. PLOS ONE. https://doi.org/10.1371/journal.pone.0303011
Vancouver
Luu TNN, Dinh DX, Tran TX, Tran TB, Tran HT, Pham KHT, et al. Health-state utility of patients with HER2-positive breast cancer in Vietnam: A multicenter cross-sectional study. PLOS ONE. 2024. doi:10.1371/journal.pone.0303011
BibTeX
@article{Luu2024,
author = {Luu, Tram Nguyen Nguyet and Dinh, Dai Xuan and Tran, Thinh Xuan and Tran, Thang Binh and Tran, Huong Thanh and Pham, Kiet Huy Tuan and Nguyen, Huong Thi Thanh},
title = {Health-state utility of patients with HER2-positive breast cancer in Vietnam: A multicenter cross-sectional study},
journal = {PLOS ONE},
year = {2024},
doi = {10.1371/journal.pone.0303011}
}
EUVIMED